Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine (CoronaVac) co-administered with an inactivated quadrivalent influenza vaccine: A randomized, open-label, controlled study in healthy adults aged 18 to 59 years in China비활성화된 4가 인플루엔자 백신과 함께 투여된 SARS-CoV-2 비활성화된 백신(CoronaVac)의 면역원성 및 안전성: 중국에서 18세에서 59세 사이의 건강한 성인을 대상으로 한 무작위, 공개, 대조 연구Randomized Controlled Trial Published on 2022-08-262022-09-12 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] 95% confidence interval administration Adverse reaction antibody assigned China comparable Concomitant Concomitant administration conducted CoronaVac COVID-19 COVID-19 vaccine dose enrolled Evidence feasible first dose GMT groups healthy immune response immunogenicity inactivated Inactivated vaccine Influenza influenza vaccine Mild moderate MOST non-inferiority Occurrence Open-label participant per-protocol randomization Randomized Randomly receive regimen SARS-CoV-2 Seasonal influenza second dose seroconversion rate two-sided Vaccine Zhejiang [DOI] 10.1016/j.vaccine.2022.07.021 PMC 바로가기 [Article Type] Randomized Controlled Trial
Potential of FX06 to prevent disease progression in hospitalized non-intubated COVID-19 patients – the randomized, EU-wide, placebo-controlled, phase II study design of IXIONClinical Trial Published on 2022-08-192022-10-05 Journal: Trials [Category] SARS, 임상, [키워드] addition Administered Admission capillary Capillary leak Clinical management clinical study code coronavirus COVID-19 COVID-19 patient COVID-19 patients COVID-19 severity Deterioration disease Disease progression double-blinded drop-out Endothelial dysfunction Endpoint enrolled EudraCT Europe France FX06 Germany Hospital stay Hospitalization Hospitalized hospitalized patient Human ICU Inflammation intravenously Italy lack limitation Lithuania Lung function mammals Mild moderate multicentre Non-intubated occurred outbreak oxygen saturation Patient patient recruitment patients patients receiving placebo peptide per day Placebo placebo-controlled Portugal positive SARS-CoV-2 PCR Potential Prevent prevent disease progression primary endpoint problem proportion protocol randomization Randomized receiving recruitment reduce Romania SARS-CoV-2 secondary Spain stages standard care Study design subject survival systemic inflammation the WHO therapy while [DOI] 10.1186/s13063-022-06609-x PMC 바로가기 [Article Type] Clinical Trial
Attractive targeted sugar bait phase III trials in Kenya, Mali, and Zambia케냐, 말리, 잠비아에서 매력적인 표적 설탕 미끼 3상 시험Clinical Trial Published on 2022-08-092022-09-11 Journal: Trials [Category] 말라리아, 임상, 치료제, [키워드] adaptive ARMS Attractive targeted sugar bait children Cluster cluster separation Cluster-randomized controlled trial Clusters Cohort Contamination Controlled trial core covariate covariates COVID-19 pandemic detect determine dinotefuran Effects External validity Follow-up Imbalance IMPROVE incidence include insecticidal insecticide interim analysis internal validity Intervention Kenya kill Longevity malaria morbidity mosquito density Open-label open-label design phase III trial Prevalence Primary outcome Primary outcomes randomization receive reduce reduction in reductions in Restricted resulting risk Sample size secondary outcome strength Structure sugar threat Transmission transmission pattern Trial Two-arm Validity Variation vector vector control vectors [DOI] 10.1186/s13063-022-06555-8 PMC 바로가기 [Article Type] Clinical Trial
Outpatient convalescent plasma therapy for high-risk patients with early COVID-19. A randomized placebo-controlled trialResearch article Published on 2022-08-012022-10-05 Journal: Clinical microbiology and infection : the official [Category] SARS, 임상, [키워드] antibodies benefit clinical conducted convalescent plasma Convalescent plasma therapy Course COVID-19 death determine died disease severity double blind duration of symptoms Effectiveness Endpoint enrolment Follow-up hazard ratio high-risk patient highest Hospital admission Hospitalized ICU admission IMPROVE in viral median age multicentre objective Odds ratio Older Outpatient outpatients Patient PCR primary endpoint randomization randomized placebo-controlled trial randomized trial recruitment Result risk factor RNA secondary severe COVID-19 Symptom symptom duration symptom onset symptomatic Symptoms the disease therapy for COVID-19 vaccination Viral RNA [DOI] 10.1016/j.cmi.2022.08.005 [Article Type] Research article
Senicapoc treatment in COVID-19 patients with severe respiratory insufficiency-A randomized, open-label, phase II trialClinical Trial Published on 2022-08-012022-10-05 Journal: Acta Anaesthesiologica Scandinavica [Category] COVID19(2023년), SARS, 임상, [키워드] 28-day mortality 95% CI Administered ARDS baseline Characteristics Concentration control group COVID-19 COVID-19 patient Denmark determine ICU IMPROVE intensive care unit Intervention IQR kPa mean difference median no difference Open-label outcomes PaO Patient patients with COVID-19 Primary outcome randomization Randomized respiratory insufficiency SARS-CoV-2 Senicapoc significantly lower standard care Treatment Trial Ventilation [DOI] 10.1111/aas.14072 PMC 바로가기 [Article Type] Clinical Trial
Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19 : A Randomized, Placebo-Controlled Trial코로나19의 바이오마커, 호흡기 중재 및 의료 서비스에 대한 몰누피라비르의 효과 : 무작위, 위약 대조 시험Randomized Controlled Trial Published on 2022-08-012022-09-11 Journal: Annals of internal medicine [Category] COVID19(2023년), MERS, SARS, 바이오마커, 임상, [키워드] 95% CI Analysis assigned baseline benefit C-reactive protein C-reactive protein (CRP Care change clinical benefit clinically Concentration COVID-19 CRP death discharge discharged double-blind Effect evaluated faster Hospitalization Hospitalized identify immunized improvement Improvements Inc Invasive mechanical ventilation less LLC median medical service medical services Mild mild to moderate Mild to moderate COVID-19 Moderate COVID-19 molnupiravir Older oxygen oxygen saturation participant performed Phase 3 Placebo placebo-controlled placebo-treated participant placebo-treated participants potential clinical benefit progression randomization Randomized Randomly receiving reduction in Relative risk respiratory respiratory intervention respiratory interventions risk risk factor Risk factors risk reduction SARS-CoV-2 secondary service severe disease Sharp subsidiary therapy Trial [DOI] 10.7326/M22-0729 PMC 바로가기 [Article Type] Randomized Controlled Trial
Plant formulation ATRICOV 452 in improving the level of COVID-19 specific inflammatory markers in patientsResearch article Published on 2022-08-012022-10-05 Journal: Contemporary Clinical Trials Communications [Category] 바이오마커, 신약개발, 임상, [키워드] adverse event assigned Care clinical trial conducted COVID-19 COVID-19 patient CTRI determine dose dropped effective Efficacy evaluate faster Frequency healthcare healthy healthy volunteer hospital Human Importance IMPROVE Inflammatory marker inflammatory markers objective organ system oxygen Patient phase Phase 1 Phase 2 phase 2 trial Placebo plant Plant formulation (ATRICOV 452) primary analysis population randomization receive reduce Registration Result Safe setting Standard of care Support therapeutic intervention Tolerability treatment group Trial Volunteer [DOI] 10.1016/j.conctc.2022.100961 [Article Type] Research article
The short-term effect of different chlorhexidine forms versus povidone iodine mouth rinse in minimizing the oral SARS-CoV-2 viral load: An open label randomized controlled clinical trial studyRandomized Controlled Trial Published on 2022-07-292022-10-05 Journal: Medicine [Category] COVID19(2023년), SARS, 임상, [키워드] ARMS assigned baseline collected conducted control group Controlled clinical trial COVID-19 E gene Efficiency evaluated form four group group Intervention less male open label P-value participant Patient povidone randomization Randomized real time PCR recruited reduction S gene Saliva salivary SARS-CoV-2 SARS-CoV-2 viral second significant decrease statistically significant difference subject the SARS-CoV-2 threshold Viral load was collected was recorded [DOI] 10.1097/MD.0000000000028925 PMC 바로가기 [Article Type] Randomized Controlled Trial
When underlying biology threatens the randomization principle — initial gout flares of urate-lowering therapy Reviews Published on 2022-07-252022-10-05 Journal: Nature reviews. Rheumatology [Category] 임상, [키워드] Analysis benefit Care Characteristics clinical trials dominant Evidence excluded expected flare generate Gout increase in Inflammatory response initial measure methodological occur paradoxical participant randomization Randomized risk robust scrutiny therapy Trial [DOI] 10.1038/s41584-022-00804-5 [Article Type] Reviews
Effects of Structured Supervised Exercise Training or Motivational Counseling on Pregnant Women’s Physical Activity Level: FitMum – Randomized Controlled TrialRandomized Controlled Trial Published on 2022-07-202022-10-04 Journal: Journal of Medical Internet Research [Category] 임상, [키워드] 95% CI activity addition adjusted Adverse age Analysis association Attendance average baseline Changing commercial activity tracker complementary Compliance Controlled counseling COVID-19 Digital health doubly labeled water Effect effective evaluate the effect event EXE exercise fitness Garmin gold standard groups Health health outcome healthy hypothese IMPROVE inactive intensity Intervention intervention group investigated IQR Maternal Maternal Health maternity measure median motivation not affect not differ Offering participant performed physical physical activity physical activity questionnaire pregnancies Pregnancy pregnant pregnant women Primary outcome primary outcome analysis randomization Randomized Randomized controlled trial RCT recommendation Registered Safe Serious Adverse Event standard care tracker training was measured was performed women women's health would increase [DOI] 10.2196/37699 PMC 바로가기 [Article Type] Randomized Controlled Trial